Çocukluk Çağında Hematopoetik Kök Hücre Nakli

Zeynep Karakaş; Tunç Fışgın

Review

Çocukluk Çağında Hematopoetik Kök Hücre Nakli

Year 2019, Volume: 11 Issue: 6, 273 - 279, 01.12.2019

Zeynep Karakaş Tunç Fışgın

Abstract

Hematopoietik kök hücre nakli malin ve malin olmayan hastalığı olan çocuklarda
iyileştirici bir tedavi yöntemi olarak kabul edilmektedir. İlk kemik iliği nakli 1957
yılında D Thomas tarafından yapılmıştır. HLA gruplarının tanımlanması ve kullanılmasından
sonra transplantasyon başarısı artmış ve daha yaygın kullanılmaya başlanmıştır.
Bugün hematolojik malignite, immün yetmezlik, hemoglobinopati, kemik iliği
yetmezlikleri ve doğuştan metabolizma hastalıklarında son tedavi modeli olarak
kullanılmaktadır.

Keywords

Hematopoietik kök hücre, hücre, nakil

References

1. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune
disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50 (8): 1037-56.
2. Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-96.
3. Buckley RH, Lucas ZJ, Hattler BG, et al. Defective cellular immunity associated with chronic mucocutaneous moniliasis
and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. Clin Exp Immunol 1968; 3 (2): 153-69.
4. Bach FH, Albertini RJ, Joo P, et al. Bone marrow transplantation in a patient with Wiskott-Aldrich syndrome. Lancet 1968; 2 (7583): 1364-66.
5. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor pediatric
allogeneic transplantation: a consensus statement from the Children’s Oncology Group (COG) Transplant Discipline Committee
and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006; 46 (4): 414-21.
6. Yesilipek MA, Hazar V, Küpesiz A, Kizilörs A, Uguz A, Yegin O. Peripheral blood stem cell transplantation in children with betathalassemia. Bone Marrow Transplant 2001; 28 (11): 1037-40.
7. Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric
blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant 2005; 35 (4): 361-67.
8. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest:
ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006; 46 (4): 422-33.
9. Rocha V, Gluckman E. Eurocord-Netcord registry and European Blood and Marrow Transplant group. Improving outcomes
of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009; 147 (2): 262-74.
10. Brunstein CG, Weisdorf DJ. Future of cord blood for oncology uses. Bone Marrow Transplant 2009; (44): 699-707.
11. Kögler G, Critser P, Trapp T, Yoder M. Future of cord blood for non-oncology uses. Bone Marrow Transplant 2009; (44): 683-97.
12. Yeşilipek MA. Çocuklarda hematopoetik kök hücre nakli. Türk Ped Arş 2014; 49: 91-98.
13. Gratwohl A. Principals of conditioning. In: Apperly J, Carreras E, Gluckman E Grawthol A, Masszi T, (eds). Hematopoetic
Stem Cell Transplantation, The EBMT Handbook. European School of Hematology, 2008: 128-44.
14. Kansoy S. Çocukluk çağı solid tümörlerinde HKH naklinin yeri. 9. Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, 3-5 Mart 2016, Antalya, s: 32-34.
15.Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines
from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21 (11): 1863-69.
16. Indications for HSCT in Children- UK Paediatric BMT Group 2015, UK Paediatric BMT Group HSCT Indications, 15 October 2015.
17. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50 (8): 1037-56.
18. Nucci M, Andrade F, Vigorito A, et al. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transpl Infect Dis 2003; 5: 167-73.
19. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility
and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-80.
20. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-91.
21. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after haematopoietic cell transplantation: joint recommendations of the
European Group for Blood and Marrow Transplantation, Centre for International, Blood and Marrow Transplant Research,
and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006; 37: 249-61.
22. Cohen A, Békássy AN, Gaiero A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41 (Suppl 2): S43-48.
23. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-58.
24. Dietz AC, Duncan CN, Alter BP, et al. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic
Cell Transplantation (HCT): Defining the Unique Late Effects of Children Undergoing HCT for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant 2016: S1083-8791 (16) 30396-2.
Bu Makale Klinik Tıp Pediatri Dergisi’nin Cilt 8 Sayı 6 Kasım - Aralık 2016 saysından alınarak tıpkısının aynısı olarak yayınlamıştır.

Year 2019, Volume: 11 Issue: 6, 273 - 279, 01.12.2019

Zeynep Karakaş Tunç Fışgın

Abstract

References

1. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune
disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50 (8): 1037-56.
2. Thomas ED, Lochte HL, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957; 257: 491-96.
3. Buckley RH, Lucas ZJ, Hattler BG, et al. Defective cellular immunity associated with chronic mucocutaneous moniliasis
and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. Clin Exp Immunol 1968; 3 (2): 153-69.
4. Bach FH, Albertini RJ, Joo P, et al. Bone marrow transplantation in a patient with Wiskott-Aldrich syndrome. Lancet 1968; 2 (7583): 1364-66.
5. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR. Use of G-CSF in matched sibling donor pediatric
allogeneic transplantation: a consensus statement from the Children’s Oncology Group (COG) Transplant Discipline Committee
and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006; 46 (4): 414-21.
6. Yesilipek MA, Hazar V, Küpesiz A, Kizilörs A, Uguz A, Yegin O. Peripheral blood stem cell transplantation in children with betathalassemia. Bone Marrow Transplant 2001; 28 (11): 1037-40.
7. Pulsipher MA, Levine JE, Hayashi RJ, et al. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric
blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant 2005; 35 (4): 361-67.
8. Pulsipher MA, Nagler A, Iannone R, Nelson RM. Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest:
ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006; 46 (4): 422-33.
9. Rocha V, Gluckman E. Eurocord-Netcord registry and European Blood and Marrow Transplant group. Improving outcomes
of cord blood transplantation: HLA matching, cell dose and other graft- and transplantation-related factors. Br J Haematol 2009; 147 (2): 262-74.
10. Brunstein CG, Weisdorf DJ. Future of cord blood for oncology uses. Bone Marrow Transplant 2009; (44): 699-707.
11. Kögler G, Critser P, Trapp T, Yoder M. Future of cord blood for non-oncology uses. Bone Marrow Transplant 2009; (44): 683-97.
12. Yeşilipek MA. Çocuklarda hematopoetik kök hücre nakli. Türk Ped Arş 2014; 49: 91-98.
13. Gratwohl A. Principals of conditioning. In: Apperly J, Carreras E, Gluckman E Grawthol A, Masszi T, (eds). Hematopoetic
Stem Cell Transplantation, The EBMT Handbook. European School of Hematology, 2008: 128-44.
14. Kansoy S. Çocukluk çağı solid tümörlerinde HKH naklinin yeri. 9. Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, 3-5 Mart 2016, Antalya, s: 32-34.
15.Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: Guidelines
from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015; 21 (11): 1863-69.
16. Indications for HSCT in Children- UK Paediatric BMT Group 2015, UK Paediatric BMT Group HSCT Indications, 15 October 2015.
17. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015; 50 (8): 1037-56.
18. Nucci M, Andrade F, Vigorito A, et al. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transpl Infect Dis 2003; 5: 167-73.
19. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility
and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-80.
20. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH. Acute and chronic graft-versus-host disease after allogeneic peripheral blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001; 19: 3685-91.
21. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after haematopoietic cell transplantation: joint recommendations of the
European Group for Blood and Marrow Transplantation, Centre for International, Blood and Marrow Transplant Research,
and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT). Bone Marrow Transplant 2006; 37: 249-61.
22. Cohen A, Békássy AN, Gaiero A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant 2008; 41 (Suppl 2): S43-48.
23. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-58.
24. Dietz AC, Duncan CN, Alter BP, et al. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic
Cell Transplantation (HCT): Defining the Unique Late Effects of Children Undergoing HCT for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant 2016: S1083-8791 (16) 30396-2.
Bu Makale Klinik Tıp Pediatri Dergisi’nin Cilt 8 Sayı 6 Kasım - Aralık 2016 saysından alınarak tıpkısının aynısı olarak yayınlamıştır.

There are 38 citations in total.

Details

Primary Language	Turkish
Subjects	Internal Diseases
Journal Section	makale
Authors	Zeynep Karakaş This is me Tunç Fışgın This is me
Publication Date	December 1, 2019
Published in Issue	Year 2019 Volume: 11 Issue: 6

Cite

APA	Karakaş, Z., & Fışgın, T. (2019). Çocukluk Çağında Hematopoetik Kök Hücre Nakli. Klinik Tıp Pediatri Dergisi, 11(6), 273-279.
AMA	Karakaş Z, Fışgın T. Çocukluk Çağında Hematopoetik Kök Hücre Nakli. Pediatri. December 2019;11(6):273-279.
Chicago	Karakaş, Zeynep, and Tunç Fışgın. “Çocukluk Çağında Hematopoetik Kök Hücre Nakli”. Klinik Tıp Pediatri Dergisi 11, no. 6 (December 2019): 273-79.
EndNote	Karakaş Z, Fışgın T (December 1, 2019) Çocukluk Çağında Hematopoetik Kök Hücre Nakli. Klinik Tıp Pediatri Dergisi 11 6 273–279.
IEEE	Z. Karakaş and T. Fışgın, “Çocukluk Çağında Hematopoetik Kök Hücre Nakli”, Pediatri, vol. 11, no. 6, pp. 273–279, 2019.
ISNAD	Karakaş, Zeynep - Fışgın, Tunç. “Çocukluk Çağında Hematopoetik Kök Hücre Nakli”. Klinik Tıp Pediatri Dergisi 11/6 (December 2019), 273-279.
JAMA	Karakaş Z, Fışgın T. Çocukluk Çağında Hematopoetik Kök Hücre Nakli. Pediatri. 2019;11:273–279.
MLA	Karakaş, Zeynep and Tunç Fışgın. “Çocukluk Çağında Hematopoetik Kök Hücre Nakli”. Klinik Tıp Pediatri Dergisi, vol. 11, no. 6, 2019, pp. 273-9.
Vancouver	Karakaş Z, Fışgın T. Çocukluk Çağında Hematopoetik Kök Hücre Nakli. Pediatri. 2019;11(6):273-9.

Download Cover Image

Article Files

Full Text